Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sphingosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.85 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.85 |
| ▸ | MAPT | P10636 | 4/20 | 0.85 |
| ▸ | CETP | P11597 | 4/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.85 |
| ▸ | THRB | P10828 | 3/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.85 |
| ▸ | GMNN | O75496 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | GLA | P06280 | 2/20 | 0.85 |
| ▸ | POLB | P06746 | 2/20 | 0.85 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.85 |
| ▸ | CCR6 | P51684 | 2/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | UBE2N | P61088 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosine SCHEMBL320150 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL16188315 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL21439824 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL31018980 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL4779279 | 1.00 | SPHK2 (0.85) | SPHK2SPHK1MEN1KMT2AMAPT | |
| SCHEMBL22986939 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL21114357 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| Sphingosine SCHEMBL2306197 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| SCHEMBL21428474 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT | |
| SCHEMBL21428477 | 0.92 | SPHK2 (1.00) | SPHK2SPHK1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711446-A1 | CELL CULTURE PRODUCT AND USE THEREOF | GUANGXIU-GAOXIN LIFE SCIENCES CO., LTD. HUNAN (CN) | 2026-03-18 | — | — | EP | claimed |
| CN-119137150-A | Engineered CD200R antibodies and uses thereof | 米罗生物有限公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2024250349-A1 | CELL CULTURE PRODUCT AND USE THEREOF | 湖南光琇高新生命科技有限公司 | 2024-12-12 | — | — | WO | claimed |
| CN-119040245-A | Method for in-vitro amplification of liver precursor cells | 中国科学院过程工程研究所 | 2024-11-29 | — | — | CN | claimed |
| CN-118879614-A | Method for promoting directional differentiation and proliferation of liver precursor cells to mature liver cells | 中国科学院过程工程研究所 | 2024-11-01 | — | — | CN | claimed |
| CN-115322946-B | Anti-hepatic fibrosis cell preparation and preparation method and application thereof | 上海赛立维生物科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116875609-A | Spherical nucleic acid targeting TLR9 with potent antitumor activity | 埃克西奎雷运营公司 | 2023-10-13 | — | — | CN | claimed |
| CN-116789798-A | Protein composition, preparation method and application thereof | 上海交通大学医学院附属仁济医院 | 2023-09-22 | — | — | CN | claimed |
| CN-116769696-A | Cell culture product and application thereof | 湖南光琇高新生命科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-112522178-B | Method for long-term culture and expansion of mature hepatocytes in vitro | 上海市东方医院（同济大学附属东方医院） | 2023-05-16 | — | — | CN | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| EP-2014653-A1 | Novel dicarboxylic acid derivatives as S1P1 receptor agonists | BIOPROJET (FR) | 2009-01-14 | — | — | EP | claimed |
| CN-101107218-A | Novel dicarboxylic acid derivatives | BIOPROJET SOC CIV (FR) | 2008-01-16 | — | — | CN | claimed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | claimed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | claimed |
| WO-2005080558-A1 | METHOD OF MODULATING CELLULAR PROCESSES | MEDVET SCIENCE PTY LTD (AU) | 2005-09-01 | — | — | WO | claimed |
| US-6098631-A | Compositions and methods for treating autoimmune disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-08-08 | — | — | US | claimed |
| WO-1999037298-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-07-29 | — | — | WO | claimed |
| EP-0825997-A1 | IDENTIFICATION OF ENANTIOMERIC LIGANDS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 1998-03-04 | — | — | EP | claimed |
| WO-1996034879-A1 | IDENTIFICATION OF ENANTIOMERIC LIGANDS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 1996-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | SPHK2 9/4885SPHK1 7/4885MEN1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.